COMPANY

Vetmab Biosciences, Inc.

“At VETmAb BIO, we are developing medications specifically designed for the species in which they will be used.” Source · checked Oct 13, 2026

Keywords: Monoclonal antibodies veterinary monoclonal antibody antibody antibodies

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 13, 2026

Sourced facts

Each item links to its source and was checked by an independent review on Oct 13, 2026 (San Diego batch).

SEC Form D raise Raised $11.44M (Form D filed Sep 29, 2026). SEC Form D 0001932050-26-000002 (Sep 29, 2026)
Evidence (1 event)
- Sep 29, 2026 · SEC Form D 0001932050-26-000002
  Name of Issuer: Vetmab Biosciences, Inc.; CIK: 1932050; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-29; Industry Group: Biotechnology; Date of First Sale: 2026-09-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11944990; Total Amount Sold: 11439990; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals